ESSA Pharma Inc.: Sm molecule drugs: castration-resistant prostate cancer. EPI-506, exp to enter clinic YE19 (second-gen compound). Developing compounds binding to N-terminus of AR and block signaling. MOA potentially overcomes resistance mechanisms currently seen in metastatic prostate cancer.
Sector/industry:
Healthcare/Drug Manufacturers
Characteristics:
Disease Space
Oncology
Listing
Public, USA
Market Cap
<100MM
Website:
Address:
999 West Broadway Street Suite 720
Vancouver, British Columbia
Canada

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.